By JULIE EGGINGTON, EKATERINA CLEARY & LEEZA OSIPENKO
When CMS issued its Request for Data below the Complete Laws to Uncover Suspicious Healthcare (CRUSH) initiative in February, it zeroed in on a long-festering drawback: fraud, waste, and abuse in laboratory testing, particularly in genetic and molecular diagnostics.
The laboratory business will reply. And when it does, its arguments will sound polished, acquainted, and deeply reassuring. They may even be both disingenuous or unproven.
If policymakers need this effort to succeed, they need to be ready to deal with three claims which have lengthy shielded problematic practices from significant oversight.
Declare 1: Fraud, waste and abuse is proscribed to some dangerous actors
Count on labs to argue that fraud, waste, and abuse is uncommon, remoted, and already addressed by enforcement actions. The narrative will characteristic a handful of egregious cases, introduced as outliers in an in any other case reliable ecosystem.
However the issue just isn’t a number of rotten apples. It’s the orchard’s design.
Take “code stacking” for instance, during which laboratories invoice a number of particular person genetic take a look at codes slightly than a single panel code, usually inflating reimbursement. In one analysis, laboratories used between 1 and 12 billing codes for hereditary most cancers panels with the identical indications for testing, with estimated common expenses starting from $679 to $8,589 for ostensibly comparable checks. The repetition of those behaviors throughout firms suggests systemic incentives, not remoted misconduct.
Ample Medicare billing knowledge, whistleblower cases, and Department of Justice settlements level to patterns, not anomalies: high-volume genetic panels ordered with little scientific justification, molecular pathology checks billed below grab bag and overly permissive billing codes, and aggressive marketing and patient harvesting practices concentrating on weak populations.
A key driver is opacity. Many laboratory-developed checks (LDTs) are marketed under similar or identical names regardless of significant variations in design, accuracy, and supposed use. To a clinician or payer, they seem interchangeable. In actuality, they aren’t.
This naming ambiguity permits lower-quality checks to trip the coattails of better-validated ones, whereas nonetheless commanding reimbursement. Fraud, on this context, just isn’t all the time a dramatic act. It’s usually embedded in routine billing.
Declare 2: Precision drugs superior by genetics is value the fee as a consequence of improved affected person outcomes
The second argument will enchantment to aspiration. Labs will emphasize that genetic testing is the spine of precision drugs and subsequently a worthwhile funding for CMS, regardless of the ballooning prices.
Laboratory lobbyists and business teams will use the ‘age of precision drugs’ argument to justify the truth that genetic testing is now costing Medicare nearly as a lot as all different outpatient laboratory testing mixed. In the latest evaluation from 2024 Medicare data, genetic checks accounted for 43% ($3.6 billion) of whole Medicare outpatient laboratory spending, regardless of representing solely 5% of all Medicare outpatient laboratory checks carried out.
There’s some fact right here to the worth of genetic checks. Selected genetic tests have demonstrated clear scientific utility, bettering analysis, or guiding therapy that has resulted within the extension of life.
However the leap from “some” checks resulting in improved affected person outcomes to “most” checks resulting in improved affected person outcomes is the place the argument breaks down.
The proof base for a lot of marketed genetic and molecular checks remains thin, heterogeneous, or entirely absent. Medical utility, within the uncommon situations the place customers or a take a look at developer has demonstrated it, is usually prolonged as a halo over different checks from completely different labs providing equally marketed checks. Whereas the me-too unproven checks share practical branding and billing codes with the confirmed take a look at, they usually differ in methodology or efficiency in nontransparent methods. Briefly, as a consequence of inherent variations in methodologies, the me-too checks could not enhance affected person outcomes on the identical effectiveness because the confirmed take a look at, and maybe in no way.
This isn’t precision drugs. It’s approximation at scale.
For policymakers, the excellence issues. With out proof {that a} take a look at informs scientific selections in a approach that improves well being, its worth to Medicare and Medicaid stays unproven.
If labs want to declare that their checks save or enhance lives, they need to reveal it for every distinct take a look at, whether or not or not it’s market chief checks or the me-too checks.
Declare 3: Oversight on labs slows innovation on the expense of lives saved
Lastly, count on labs to challenge a warning: stricter oversight of labs’ affected person recruitment and billing practices will sluggish innovation, delay entry to cutting-edge diagnostics, and in the end hurt sufferers.
This argument rests on a important assumption that has not been established, particularly that the present quantity and acceleration of precision drugs associated laboratory testing is delivering life-saving profit at scale.
In lots of instances, that proof doesn’t exist, or exists to the contrary.
Innovation in healthcare just isn’t outlined by the variety of checks medical doctors order for sufferers, or the growing complexity and expense of molecular pathology testing, however by their impression on affected person outcomes. Requiring that the best sufferers obtain the best checks (which have confirmed utility), on the proper time, doesn’t inherently suppress innovation; it helps distinguish between significant advances and the noise
Well documented efforts by some genetics labs to recruit as many sufferers as attainable ends in the dilution of the true worth of genetic testing. Even when, for instance, a most cancers genetic testing laboratory has a take a look at with confirmed scientific utility for sufferers with sure cancers, testing sufferers with out the related cancers would dilute its measurable scientific utility. And because of the existence of false positives in diagnostics, testing sufferers recruited inappropriately might in the end hurt extra sufferers than the take a look at helps.
Moreover, the absence of billing requirements can distort innovation. When reimbursement is out there with out sturdy proof necessities, the market rewards proliferation over validation. With out oversight, high-quality checks should compete with lower-cost, lower-evidence options which are marketed as equal or higher than the confirmed checks.
Stricter oversight of laboratories affected person recruitment and requests for reimbursement would supply CMS alternative to make sure that the objectives of precision drugs are achieved. It might not halt innovation. It might redirect it towards demonstrable worth.
A path ahead
If CMS needs to cut back fraud, waste, and abuse in laboratory testing, it ought to focus much less on chasing particular person dangerous actors – which is proving to be an infinite recreation of whack-a-mole – and extra on correcting structural weaknesses.
That begins with transparency. Checks that differ in design or efficiency shouldn’t share indistinguishable names in billing programs. Clear differentiation would make it tougher for lower-quality checks to masquerade as established ones.
It additionally requires proof self-discipline. Protection and reimbursement needs to be tied to demonstrated scientific utility on the take a look at stage, not inferred from category-level proof.
The CRUSH RFI presents a possibility to reset expectations. The laboratory business will make its case. CMS needs to be able to look previous the acquainted narratives and ask an easier query: not whether or not a take a look at might advance drugs, however whether or not it does.
Julie Eggington is CEO of the Middle for Genomic Interpretation and founding father of Grandview Consulting. Ekaterina Cleary is a Information Scientist and Leeza Osipenko is CEO at Consilium Scientific, the place she leads the event of This submit is a part of their work at Evimeter, a quantitative framework for evaluating the energy of scientific proof supporting breakthrough medical gadgets and diagnostics, funded by Arnold Ventures.
